Table II.

Prognostic significance of Sp1 mRNA in gastric cancer.

	Overall survival		Progression-free survival
Clinicopathological features	Hazard ratio	P-value	Hazard ratio	P-value
Sex
Female	0.66 (0.39–1.11)	0.11	0.66 (0.40–1.09)	0.10
Male	0.63 (0.44–0.89)	0.01	0.57 (0.21–1.51)	0.25
TNM staging
1	0.19 (0.06–0.57)	<0.01	0.17 (0.06–0.53)	<0.01
2	0.57 (0.26–1.24)	0.15	0.47 (0.21–1.06)	0.06
3	0.60 (0.37–0.97)	0.04	0.66 (0.39–1.12)	0.12
4	0.73 (0.43–1.25)	0.25	0.74 (0.50–1.08)	0.12
T
2	0.52 (0.37–0.87)	0.01	0.61 (0.38–1.00)	0.05
3	1.29 (0.87–1.89)	0.20	1.31 (0.90–1.91)	0.16
4	0.49 (0.20–1.20)	0.11	0.44 (0.19–1.01)	0.05
N
0	0.40 (0.16–0.97)	0.04	0.39 (0.16–0.94)	0.03
1–3	0.62 (0.45–0.85)	<0.01	0.65 (0.48–0.88)	<0.01
1	0.57 (0.35–0.94)	0.02	0.56 (0.34–0.92)	0.02
2	0.54 (0.30–0.97)	0.04	0.56 (0.32–1.00)	0.05
3	1.60 (0.84–3.04)	0.15	0.70 (0.40–1.22)	0.21
M
0	0.61 (0.43–0.85)	<0.01	0.64 (0.46–0.88)	<0.01
1	0.61 (0.32–1.20)	0.15	0.62 (0.34–1.11)	0.11
Perforation complications
−	1.27 (0.85–1.90)	0.25	0.79 (0.53–1.18)	0.25
Treatment
Surgery alone	0.67 (0.48–0.94)	0.02	0.69 (0.49–0.97)	0.033
5-fluorouracil-based adjuvant	4.36 (1.64–11.6)	<0.01	3.22 (1.25–8.24)	0.01
Other adjuvant	1.58 (0.63–3.96)	0.3	0.66 (0.28–1.54)	0.34
Differentiation
Moderately-differentiated	0.48 (0.24–0.94)	0.03	0.45 (0.24–0.87)	0.02
Poorly-differentiated	1.63 (0.98–2.70)	0.06	1.54 (0.95–2.50)	0.08
Lauren's classification
Intestinal-type	0.50 (0.33–0.77)	<0.01	0.52 (0.36–0.74)	<0.01
Diffuse-type	1.43 (0.99–2.06)	0.05	1.36 (0.94–1.96)	0.10
Mixed-type	2.62 (0.57–12.02)	0.20	2.14 (0.59–7.83)	0.24
Her2 positivity
−	0.62 (0.47–0.81)	<0.01	0.69 (0.49–0.98)	0.04
+	0.65 (0.41–1.02)	0.06	0.60 (0.37–0.98)	0.04